CD44 and neoplasm: (132) found that in a GCSCs model, pantoprazole was able to increase the therapeutic sensitivity of GC to 5-fluorouracil, decrease the capacity of generating tumor spheres and the expression levels of GCSCs markers such as CD44, CD24, and Lgr5 by inhibiting the EMT/β−catenin pathways.